Faculty profile

Danny Vesprini

Back to faculty

Associate ProfessorDepartment of Radiation OncologyUniversity of Toronto

Danny Vesprini

Associate Professor

Department of Radiation Oncology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
49 publications in the last five years, latest in 2027.
Senior (last) author on 5 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

109

Publications

3,672

Citations

124

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.
Clinical and translational radiation oncology · 2027
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.
JAMA network open · 2026
Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.
BMC cancer · 2026

All 109 publications

109 publications.

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.

Alayed Y, Gopaul D, Mendez LC, Kwan W, Liu SK, Chu W, Tseng CL, Cheung P, Vesprini D, Chung H, Morton G, Correa R, Musunuru B, Davidson M, Ravi A, Deabreu A, Mamedov A, Poon E, Zhang L, Loblaw A

Clinical and translational radiation oncology2027

DOI: 10.1016/j.ctro.2026.101256 PMID: 42750816

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Tseng CL, Vesprini D, Hudson JM, Ong WL, Kennedy T, Helou J, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

JAMA network open20262 citationsOpen Access

DOI: 10.1001/jamanetworkopen.2026.0146 PMID: 41739470

Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.

Wang H, Rajagopal A, Cao K, Cimolai K, Petchiny TN, White SD, Cheung J, Loblaw A, Vesprini D, Leong H, Escueta V, Zhang L, Glicksman R, Cheung P, Wang C, Liu SK

BMC cancer2026Open Access

DOI: 10.1186/s12885-026-15854-1 PMID: 41888707

Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis

Bayrakdarian S, Hircock C, Wong HCY, Zhang L, Ding K, Karam I, Gallant F, Rakovitch E, Tran W, Soliman H

Breast Cancer Research and Treatment2026

DOI: 10.1007/s10549-026-07987-5

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

Ong WL, Davidson M, Wronski M, Kang T, Cheung P, Chu W, Chung H, Liu S, Morton G, Tseng CL, Vesprini D, Zhang L, Poon C, Loblaw A

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.08.014 PMID: 40819809

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial.

Cooper S, Alexander S, Breitkreutz D, Casey F, Christodouleas J, Dassen MG, Dell'acqua V, Dunlop A, Herbert T, Kolias P, Mitchell A, Pos FJ, Westley R, Tree AC, Van Der Heide UA, Vesprini D

BMJ open2026Senior author

DOI: 10.1136/bmjopen-2025-111791 PMID: 42097645

Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study.

Cooper S, Alexander S, Cherry C, Chick J, Dassen MG, Dunlop A, Hassan S, Herbert T, Mason F, Mitchell A, Nill S, Oelfke U, Pos F, Saifuddin M, Westley R, van der Heide UA, Vesprini D, Tree A

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026

DOI: 10.1016/j.radonc.2026.111363 PMID: 41506574

Retrospective Analysis of Acute Toxicity Following Breast Cancer Re-Irradiation.

Wang AJ, Kagan S, Zhang L, Hircock C, Bayrakdarian S, Chen H, Vesprini D, Soliman H, Chow E, Karam I

Clinical breast cancer2026

DOI: 10.1016/j.clbc.2026.07.024 PMID: 42574817

External Beam Breast and Chest Wall Re-Irradiation Following Resection of Ipsilateral Breast Cancer Recurrence: Dose-Toxicity Relationships and Long-Term Oncologic Outcomes.

Ghosh S, Soliman H, Chow E, Chen H, Leung E, Karam I, Rakovitch E, Safavi AH, Vesprini D, Czarnota GJ

Cancers2026

DOI: 10.3390/cancers18172878 PMID: 42738398

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Ong WL, Kennedy T, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

European urology oncology20259 citationsOpen Access

DOI: 10.1016/j.euo.2024.12.015 PMID: 39904690

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Danny Vesprini

Research

Latest papers

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.

Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial.

Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study.

Retrospective Analysis of Acute Toxicity Following Breast Cancer Re-Irradiation.

External Beam Breast and Chest Wall Re-Irradiation Following Resection of Ipsilateral Breast Cancer Recurrence: Dose-Toxicity Relationships and Long-Term Oncologic Outcomes.

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Frequent collaborators

Andrew Loblaw

Stanley Liu

Patrick Cheung

William Chu

Edward Chow

Gerard Morton

Hans Chung

Eileen Rakovitch

Ewa Szumacher

Hany Soliman

Irene Karam

Hanbo Chen

Justin Lee

Chia-Lin Tseng

Eric Leung

Laurence Klotz

Merrylee McGuffin

Jay Detsky

Gregory Czarnota

William Tran

Renee Korol

Paul Boutros

Geordi Pang

Claire McCann

Arjun Sahgal

Belinda Curpen

Padraig Warde

Aruz Mesci

Robert Nam

Nicole Hong

Sten Myrehaug

Brian Keller

Tara Rosewall

Ian Poon

Laura Snell

Jeremie Larouche

Ants Toi

Martin O'Malley

Pejman Maralani

Marko Popovic